Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with the pharma for

Read the full 381 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE